Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 12/20 | 0.54 |
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19284814 | 1.00 | APLNR (0.54) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL19284750 | 1.00 | APLNR (0.54) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL19285308 | 0.88 | APLNR (0.52) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL19285307 | 0.88 | APLNR (0.52) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL19285419 | 0.88 | APLNR (0.52) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL17542305 | 0.81 | APLNR (0.61) | APLNRTAS2R14 | |
| SCHEMBL17542467 | 0.81 | APLNR (0.61) | APLNRTAS2R14 | |
| SCHEMBL17542070 | 0.81 | APLNR (0.61) | APLNRTAS2R14 | |
| SCHEMBL23670258 | 0.80 | APLNR (0.57) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL23670256 | 0.80 | APLNR (0.57) | APLNRTAS2R14PTGESTAS2R8CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2017147410-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | APLNR 3701/4885TAS2R14 4809/4885PTGES 3380/4885 |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | APLNR 3701/4885TAS2R14 4809/4885PTGES 3380/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | APLNR 3701/4885TAS2R14 4809/4885PTGES 3380/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | APLNR 3701/4885TAS2R14 4809/4885PTGES 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.